These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 25478000)

  • 1. Policosanol attenuates statin-induced increases in serum proprotein convertase subtilisin/kexin type 9 when combined with atorvastatin.
    Guo YL; Xu RX; Zhu CG; Wu NQ; Cui ZP; Li JJ
    Evid Based Complement Alternat Med; 2014; 2014():926087. PubMed ID: 25478000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia.
    Khera AV; Qamar A; Reilly MP; Dunbar RL; Rader DJ
    Am J Cardiol; 2015 Jan; 115(2):178-82. PubMed ID: 25432415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of effects of pitavastatin versus pravastatin on serum proprotein convertase subtilisin/kexin type 9 levels in statin-naive patients with coronary artery disease.
    Nozue T; Hattori H; Ishihara M; Iwasaki T; Hirano T; Kawashiri MA; Yamagishi M; Michishita I
    Am J Cardiol; 2013 May; 111(10):1415-9. PubMed ID: 23433768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome.
    Altunkeser BB; Tuncez A; Ozturk B; Tezcan H; Ates MS; Yilmaz C; Yalcin MU; Aygul N; Demir K
    Coron Artery Dis; 2019 Jun; 30(4):285-290. PubMed ID: 30741744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.
    Arsenault BJ; Petrides F; Tabet F; Bao W; Hovingh GK; Boekholdt SM; Ramin-Mangata S; Meilhac O; DeMicco D; Rye KA; Waters DD; Kastelein JJP; Barter P; Lambert G
    J Clin Lipidol; 2018; 12(1):130-136. PubMed ID: 29103916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials.
    Sahebkar A; Simental-Mendía LE; Guerrero-Romero F; Golledge J; Watts GF
    Diabetes Obes Metab; 2015 Nov; 17(11):1042-55. PubMed ID: 26183252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased sortilin and its independent effect on circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) in statin-naive patients with coronary artery disease.
    Hu D; Yang Y; Peng DQ
    Int J Cardiol; 2017 Jan; 227():61-65. PubMed ID: 27846466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor exerts greater efficacy than atorvastatin on improvement of brain function and cognition in obese rats.
    Arunsak B; Pratchayasakul W; Amput P; Chattipakorn K; Tosukhowong T; Kerdphoo S; Jaiwongkum T; Thonusin C; Palee S; Chattipakorn N; Chattipakorn SC
    Arch Biochem Biophys; 2020 Aug; 689():108470. PubMed ID: 32592802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma proprotein convertase subtilisin kexin type 9 is a heritable trait of familial combined hyperlipidaemia.
    Brouwers MC; van Greevenbroek MM; Troutt JS; Bonner Freeman A; Lu A; Schaper NC; Konrad RJ; Stehouwer CD
    Clin Sci (Lond); 2011 Nov; 121(9):397-403. PubMed ID: 21539517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Sanchez RJ; Klimchak AC; Khan I; Sasiela WJ; Reynolds MR; Rosenson RS
    Am J Cardiol; 2019 Apr; 123(8):1202-1207. PubMed ID: 30736965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Statin Therapy on Plasma Proprotein Convertase Subtilisin/kexin Type 9 and Sortilin Levels in Statin-Naive Patients with Coronary Artery Disease.
    Nozue T; Hattori H; Ogawa K; Kujiraoka T; Iwasaki T; Michishita I
    J Atheroscler Thromb; 2016 Jul; 23(7):848-56. PubMed ID: 26797266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Aortic Calcification by Policosanol in Dyslipidemic Rabbits Is Enhanced by Pentoxifylline: Potential Role of PCSK9.
    Elseweidy MM; Mohamed HE; Elrashidy RA; Atteia HH; Elnagar GM
    J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):551-560. PubMed ID: 29742924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum PCSK9 Levels Distinguish Individuals Who Do Not Respond to High-Dose Statin Therapy with the Expected Reduction in LDL-C.
    Taylor BA; Panza G; Pescatello LS; Chipkin S; Gipe D; Shao W; White CM; Thompson PD
    J Lipids; 2014; 2014():140723. PubMed ID: 25136459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.
    Costet P; Hoffmann MM; Cariou B; Guyomarc'h Delasalle B; Konrad T; Winkler K
    Atherosclerosis; 2010 Sep; 212(1):246-51. PubMed ID: 20619837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
    Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
    Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
    Simonen P; Stenman UH; Gylling H
    Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects.
    Anderson JM; Cerda A; Hirata MH; Rodrigues AC; Dorea EL; Bernik MM; Bertolami MC; Faludi AA; Hirata RD
    J Clin Lipidol; 2014; 8(3):256-64. PubMed ID: 24793346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study.
    Huijgen R; Boekholdt SM; Arsenault BJ; Bao W; Davaine JM; Tabet F; Petrides F; Rye KA; DeMicco DA; Barter PJ; Kastelein JJ; Lambert G
    J Am Coll Cardiol; 2012 May; 59(20):1778-84. PubMed ID: 22575316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9.
    Chen IC; Tseng WK; Li YH; Tseng SY; Liu PY; Chao TH
    Oncotarget; 2017 Dec; 8(64):108042-108053. PubMed ID: 29296222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.